In the last two decades, >30% of drugs withdrawals from the market were due to cardiac toxicity, where unintended interactions with ion channels disrupt the heart's normal electrical function. Consequently, all new drugs must undergo preclinical testing for cardiac liability, adding to an already expensive and lengthy process. Recognition that proarrhythmic effects often result from drug action on multiple ion channels demonstrates a need for integrative and comprehensive measurements. Additionally, patient-specific therapies relying on emerging technologies employing stem-cell derived cardiomyocytes (e.g. induced pluripotent stem-cell-derived cardiomyocytes, iPSC-CMs) require better screening methods to become practical. However, a high-throughput, cost-effective approach for cellular cardiac electrophysiology has not been feasible.
INTRODUCTION
The research and development of new drugs remains limited in scalability, contributing to higher costs and longer timelines for their arrival onto the market [1] . Currently, among the most popular drug targets are voltage-and ligandgated ion channels, where estimated worldwide sales of ion-channel-targeting drugs are over $12 billion [2] [3] [4] . Ion channels, which are the fundamental electrophysiological structures driving cellular functionality, are desirable drug targets as they are cell-membrane localized, thus easily targeted, and are integral components for the heart, brain, and other life-sustaining functions. However, many new ion-channel targeting drugs lack specificity for particular cell-types, leading to undesired side effects. This has resulted in multiple cases of drugs being withdrawn from the market after approval. In particular, over 30% of such withdrawals have been due to cardiotoxicity, [5] where drugs have been found to disrupt normal electrical activity of the heart and induce arrhythmias, even after the drug has undergone the lengthy and expensive drug approval process. Because of this, all new drugs are required to be tested for cardiac liability -their propensity to induce electrical disturbances in the heart that can later develop into fatal arrhythmias [6] .
In order to improve drug screening, safety testing, and streamline the drug development process, high-throughput methods for preclinical testing at the cellular and multicellular level are necessary. Traditional methods for performing electrophysiological measurements are able to provide a more complete picture of a drug's action on heart cells (cardiomyocytes); however, it is not a scalable process. To lessen this bottleneck, new technical developments have provided means for increased throughput testing [2, 4] . However, they are unable to show a complete picture of electrical function. Often, they cannot characterize a drug's action on multiple ion channels simultaneously, discern drug action at variable beating rates, use relevant cardiomyocyte or cardiomyocyte-like cell types, and/or study electrical activity over a large spatial area [6] [7] [8] [9] [10] . Recently, methods for developing human patient-derived cardiomyocytes (induced pluripotent stem cell derived, iPSC-CMs) provide a promising means for developing patient-specific environments for studying drug effects and creating patient-tailored therapies [11, 12] . However, because screening methods for relevant phenotypes characteristic of mature cardiac cells remains inefficient, high-throughput methods for automation and scaling are necessary for the technology to be clinically applicable.
An all-optical approach to cardiac electrophysiology [13] [14] [15] provides an elegant, contactless solution for controlling and recording electrical activity of the heart at both the cellular and tissue level, making it capable of overcoming limitations to current high-throughput screening approaches. Optogenetics, where cells are genetically modified to express lightsensitive proteins, provide a means for fast, precise control of cellular electrophysiology. For example, the genetically encoded light-sensitive actuator Chanelrhodopsin-2 (ChR2) can be used to optically depolarize the cell membrane in order to stimulate cells individually or simultaneously [16] [17] [18] . Similarly, genetically encoded fluorescent reporters or synthetic dyes can be used to optically measure electrophysiological responses [15, 19, 20] .
Here we present OptoDyCE, a fully automated system for all-optical cardiac electrophysiology testing, employing the depolarizing, optically sensitive ion channel Channelrhodopsin-2 (ChR2) to manipulate and record electrical activity in cardiomyocytes. We demonstrate dynamic interrogation and readout of both voltage and calcium signals using synthetic dyes, which can provide high-content data vital for understanding electrophysiological responses to drug dosing, as well as be used in phenotypic screening of iPSC-CMs, and other studies of cardiac electrical function. Additionally, the system is inherently parallelized, as it is able to interrogate hundreds of cells simultaneously, allowing for the study of spatiotemporal phenomenon.
MATERIALS AND METHODS

Primary Cardiomyocyte Isolation and Culture
Primary cardiomyocytes (CMs) were isolated as described previously. [21, 22] To summarize, neonatal (2-3 day old) Sprague-Dawley rats were sacrificed and ventricular tissue was dissected per an approved Stony Brook University IACUC protocol. The tissue was shaken and digested overnight at 4°C using 1mg/mL trypsin (US Biochemicals, Cleveland, OH) in Hanks' Balanced Salt Solution (HBSS, GIBCO Invitrogen, Carlsbad, CA). After approximately twelve to fourteen hours, the tissue was serially digested using 1mg/mL collagenase (Worthington Biomedical, Lakewood, NJ) in HBSS at 37°C and pipetted into conical tubes and placed on ice. After centrifugation, cells were resuspended in culture medium M199 (GIBCO) supplemented with 12 µM L-glutamine (GIBCO), 0.05 µg/mL penicillinstreptomycin (Mediatech Cellgro, Kansas City, MO), 0.2 µg/mL vitamin B12 (Sigma Aldrich, St. Louis, MO), 10 mM HEPES (GIBCO), 3.5 mg/mL D-(+)-glucose (Sigma Aldrich) and 10% fetal bovine serum, FBS (GIBCO). Fibroblasts were removed via a two-step pre-plating process, where the cell suspension was plated in a flask and incubated (37°C, 5% CO2) for 45-60 minutes and switched to a new flask and the incubation repeated. CMs were then counted using a hemocytometer prior to plating in glass-bottom 96-well plates.
Optogenetic Actuation: Gene Delivery
Introduction of the optogenetic actuator was performed via direct gene delivery into cardiomyocytes using an adenovirus (ChR2-CM) [23, 24] . Adenoviral delivery of ChR2(H134R) to primary cardiomyocytes in suspension has been described previously. [24] Briefly, we used the plasmid pcDNA3.1/hChR2(H134R)-EYFP from Addgene (Cambridge, MA) to develop an adenoviral construct (pBR322 backbone) with a ubiquitous CMV promoter. First-generation adenovirus was generated by homologous recombination of the Ad-CMV-ChR2-eYFP into pTG3604; further propagation and purification of the virus genomes was done by transfection into HEK293 cells and CsC1 banding.
CMs were re-suspended in 2% FBS M199 after counting and diluted to 1.125x10 6 cells/mL and infected using an optimized multiplicity of infection (MOI) of 15 for 2 hours in an incubator (37°C, 5% CO2) with gentle agitation every 20 minutes. The MOI had been optimized during preliminary experiments to achieve >95% ChR2 expression in CMs within 48 hours using titer of 10 12 units/mL diluted in PBS, confirmed by eYFP reporter visualization and minimal cell death (by propidium iodide staining). [13, 24] After 2 hours, the cell suspension was centrifuged and culture medium was removed and replaced with fresh 10% FBS M199 for plating.
Cell Plating
Fibronectin (50 µg/mL) was diluted in PBS and pipetted onto 96-well glass-bottom plates (In Vitro Scientific) and incubated at 37°C for at least two hours prior to cell plating. Cells were plated in 10% FBS M199 media; on day 2, the media was replaced with 2% FBS M199 until the day of experiments. Non-infected control CMs and ChR2-CM cells were plated using a concentration of 1.125 x 10 6 cells/mL to achieve a plating density of 470,000 cells/cm 2 . After centrifugation, the media was removed and the cells were re-suspended in fresh 10% FBS M199 to achieve the same density of plating as the control cardiomyocytes.
Immunocytochemistry
The expression of ChR2 in primary rat cardiomyocytes was confirmed using antibody staining and confocal imaging (Figure 1 ). Samples were fixed in 3.7% formaldehyde, and cell membrane permeabilization was performed by incubating samples in 0.02% TritonX-100 for 5 minutes. To label cardiomyocytes, the cells were labeled with mouse anti-α-actinin primary antibody (Sigma Aldrich) and Alexa Fluor 647 goat anti-mouse IgG secondary antibody (Invitrogen), which were diluted using 1% bovine serum albumin (Amersham PLC, Amersham, UK) and 1% FBS was used as a blocking agent. The eYFP reporter on ChR2 was imaged to observe expression of the channel. Imaging was done using the Olympus FluoViewTM FV1000 confocal system with acquisition rate at 4 μs/pixel. Gain was kept constant for control and test groups to normalize and exclude autofluorescence contributions. 
Spectral Considerations
Optical recording primarily involves two classes of synthetic fast fluorescent dyes: voltage and intracellular calcium. One of the key challenges to designing an all-optical electrophysiology system is minimizing spectral overlap of actuators (entities driving or suppressing cell activity) and sensors (fluorescent probes that undergo spectral shifts in response to physiological changes). Commonly used voltage sensors include the styryl dyes, such as the blue-green excited Di-8-ANEPPS, which are not particularly efficient and overlap spectrally with the wavelengths of commonly used optogenetic actuators such as ChR2. More recently, new near-infrared (650 nm) dyes, such as di-4-ANBDQBS (spectrum in Figure 2A ), have provided a means of further spectral separation from actuators. Calcium dyes are also of particular interest, due to the link between electrical activity and intracellular calcium [25, 26] . Unlike potentiometric dyes, commonly used calcium dyes, such as Rhod-4-AM (spectrum in Figure 2A ), have much stronger optical signals. However, their affinity for Ca 2+ is vital for accurate representation of the Ca 2+ transient; higher affinity dyes can result in artificially prolonged transient recordings [25] [26] [27] .
For actuation, light-sensitive ion channels, such as the blue-wavelength excited (470 nm) depolarizing (excitatory) channel ChR2 is used [28, 29] . Figure 2A shows the action spectrum for ChR2, as well as the excitation and emission spectra for two compatible optical sensors: the calcium-sensitive probe Rhod-4 and the red-shifted voltage sensor Di-4-ANBDQBS. Many of these probes and actuators have broad absorption and emission spectra which can overlap causing issues with excitaiton and stimulation. For example, ChR2 has an intermediate deactivating green state at 520 nm after activation with blue light, meaning excitation light for dyes such as Rhod-4 could potentially affect ChR2 kinetics [30] , however in the OptoDyCE system we have not found this to cause significant effects. 
All-Optical Electrophysiology
All functional experiments were carried out 4-5 days after cell plating, at room temperature in Tyrode's solution, as previously described. [21] The optical setup, shown in Figure 2B , was built around an inverted microscope system. Illumination for optical actuation and sensing was provided by programmable LEDs in a custom built adapter. Optical actuation of ChR2 was provided by LS2, a 470 nm, LED, with a 470/28 nm bandpass filter, Factu. The components of the optical sensing light-path were selected based on the optical sensor. Voltage measurements, Vm, were recorded using the synthetic voltage-sensitive dye Di-4-ANBDQBS [31] (from Leslie Loew, University of Connecticut) with fluorescence excitation and emission peaks at 660 nm and > 700 nm, respectively. Rhod-4AM (AAT Bioquest, Sunnyvale, CA) with fluorescence excitation and emission peaks at 530 nm and 605 nm, respectively, was used for intracellular calcium, ]i: 535/50 nm). The light paths for optical sensing and actuation were combined by a dichroic mirror DM1 and directed to the sample by DM2. Emitted fluorescence was collected by the objective lens and passed through DM2 and a band-pass emission filter Fem (Vm: 700 nm long-pass; [Ca 2+ ]i: 605/70 nm bandpass) to a detector (EMCCD camera).
RESULTS
Optical recording of membrane voltage, Vm, was performed using the synthetic voltage-sensitive dye Di-4-ANBDQBS, spectrally-compatible with ChR2. Briefly, a 17.5 mM stock solution in pure ethanol was diluted to 35 µM Tyrode's solution. Cells were stained for 6 minutes in dye solution followed by a 6 minute wash in fresh Tyrode's. This wash solution was then replaced by fresh Tyrode's. Intracellular calcium, [Ca 2+ ]i, was recorded using Quest Rhod-4 AM diluted from a 0.5 mM stock solution dissolved in DMSO with 20% Pluronic to 10 µM in Tyrode's solution. Samples were stained with this solution for 20 minutes, followed by a 20 minute wash in fresh Tyrode's solution, and finally a replacement with fresh Tyrode's before experiments.
Optical imaging was performed at >200 frames per second (fps) with 4x4 binning. Optical stimulation (470 nm) was provided at pulse lengths of 5-20 ms, at 0.5-8 Hz, using irradiances of 0.4 -7 mW/mm 2 , as needed. Example data illustrating the dynamic capabilities of the OptoDyCE system are illustrated in Figure 3 . Both Vm (top) and Ca 2+ (bottom) recordings were obtained from samples plated on 96 well pates and were paced at frequencies of 1, 2, and 3 Hz. 
DISCUSSION
All-optical cardiac electrophysiology is integral for high-throughput cardiotoxicity testing, as well as improved methods for drug research and development, and for enhanced methods for treating arrhythmias. The ability for spatiallyresolved, highly-parallel dynamic stimulation is a key component for testing and understanding the generation of arrhythmias, particularly in the context of drug testing. Here we show the OptoDyCE system is capable of contactless, automated, and dynamic interrogation of cardiomyocytes, making the platform an ideal candidate for providing highthroughput screening. Additionally, the system can be easily extended to use with iPSC-CMs and other cell types, through either direct gene delivery methods or through employment of actuator-expressing somatic cells. The system is also capable of providing quantitative results, allowing for more comprehensive and precise high-content data allowing for full characterization of electrophysiological processes, which can provide an economical means for improving and streamlining the drug development process.
